Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Researchers Receive Recognition for Recent Scientific Publications

Accesswire November 27, 2019

Theralase Announces Leadership Transition

Accesswire October 31, 2019

Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds

Accesswire October 22, 2019

London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire October 7, 2019

Theralase Files Investigational New Drug Application with the FDA

Accesswire October 1, 2019

Theralase: Patient 6 No Tumours after 540 Days

Stockhouse Editorial September 30, 2019

Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment

Accesswire September 30, 2019

The Multibillion-Dollar Bladder Cancer Market Solution

Jonathon Brown September 16, 2019

Theralase Grants Stock Options

Accesswire September 16, 2019

Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire September 4, 2019

Theralase Releases Second Quarter 2019 Financial Results and Company Update

Accesswire August 29, 2019

Theralase Announces Closing of Prospectus Offering for Gross Proceeds of $17,250,000

Accesswire August 22, 2019

Theralase Announces Pricing Of Prospectus Offering

Accesswire August 1, 2019

Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment

Accesswire July 31, 2019

McGill University Health Centre Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire July 30, 2019

Theralase Enrolls First Patient into Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Accesswire July 29, 2019

Theralase Signs Agreement with Urology Organization to Provide US Clinical Study Sites for its Phase II Non Muscle Invasive Bladder Cancer Clinical Study

Accesswire July 24, 2019

Theralase Receives Notice of Acceptance for Multiwavelength Photo Dynamic Therapy from Russian Patent Office

Accesswire July 16, 2019

Theralase Releases 2019 Annual General Meeting Video Presentations

Accesswire June 28, 2019

Regulatory Updates from Health Canada and US FDA

Accesswire June 27, 2019